Comparing Costs of New Drugs in Prostate CancerComparing Costs of New Drugs in Prostate Cancer
A simplified model analyzing cost and survival finds that generic docetaxel and abiraterone are better value than cabazitaxel and sipuleucel-T. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Health | Hematology | Prostate Cancer | Taxotere